IL9R and neoplasm: T cells expressing a chimeric receptor containing the extracellular domain of IL-2R fused with the intracellular domain of IL-9R acquire features of effector T cells and show anti-tumor activity when adoptively transferred in syngeneic mouse models of melanoma and pancreatic cancer (187).